Kenvue Inc. (KVUE) Stock Analysis and Metrics

Kenvue

NYSE: KVUE

$19.25 ▲ +0.35 (+1.88%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap36.23 Bn

P/E22.34

P/S2.37

Div. Yield0.04

ROIC (Qtr)0.00

Total Debt (Qtr)8.66 Bn

Revenue Growth (1y) (Qtr)4.49

Add ratio to table…

About

Kenvue is the world’s largest pure-play consumer health company by revenue, specializing in everyday care products that bridge healthcare and consumer goods. The company operates at the intersection of science and consumer insights, delivering trusted brands that empower individuals to maintain and improve their health. With a portfolio of iconic names such as Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec, Kenvue combines scientific innovation with digital strategies to create products that are recommended by healthcare professionals and integrated into daily routines. The company markets its offerings in over 165 countries, leveraging a global footprint to address diverse consumer needs across self-care, skin health, beauty, and essential health categories.

Kenvue generates revenue through the sale of over-the-counter medicines, personal care products, and health-related solutions. Its primary products include pain relievers, allergy medications, oral care items, baby care essentials, wound care supplies, and dermatological skincare solutions. The company distributes its products through retail channels, e-commerce platforms, and direct-to-consumer initiatives, catering to both individual consumers and healthcare professionals. In the fiscal year 2025, Kenvue reported $15.1 billion in net sales, reflecting its strong market presence and broad product portfolio.

The company operates through the following segments:

• Self Care: This segment focuses on over-the-counter healthcare solutions, including cough, cold, and allergy remedies, pain care products, digestive health aids, smoking cessation tools, and eye care items. Key brands in this segment include Tylenol, Zyrtec, Benadryl, Motrin, Nicorette, and Zarbee’s. The segment also integrates digital diagnostics and telemedicine to provide personalized health offerings, enhancing accessibility and consumer engagement.

• Skin Health and Beauty: This segment encompasses face and body care, hair care, sun protection, and other beauty products. Leading brands such as Neutrogena, Aveeno, OGX, Rogaine, and Dr. Ci:Labo leverage scientific expertise and partnerships with dermatologists to deliver dermatological solutions. The segment emphasizes innovation and professional endorsements to drive consumer trust and loyalty.

• Essential Health: This segment includes oral care, baby care, wound care, and women’s health products. Major brands like Listerine, Johnson’s, BAND-AID, Desitin, and o.b. tampons address fundamental personal care needs. The segment focuses on raising standards in categories such as menstrual health, oral hygiene, and infant care, ensuring broad accessibility and reliability.

Kenvue holds a dominant position in the global consumer health industry, competing with established consumer packaged goods companies, pharmaceutical groups, and niche brands. Its key competitors include Haleon, Procter & Gamble, Reckitt Benckiser Group, Unilever, Beiersdorf, Estée Lauder, L’Oréal, Church & Dwight, Colgate-Palmolive, and Kimberly-Clark. The company’s competitive advantages stem from its extensive portfolio of science-backed, trusted brands, deep consumer insights, and digital marketing capabilities. Kenvue’s focus on innovation, coupled with its global scale and strong relationships with healthcare professionals, enables it to maintain leadership in highly competitive markets. Additionally, its commitment to sustainability and corporate governance further strengthens its industry standing.

Kenvue serves a diverse customer base spanning individual consumers, healthcare professionals, and retail partners worldwide. Its products are distributed through major retail chains, pharmacies, e-commerce platforms, and direct-to-consumer channels. The company’s brands are embedded in daily consumer routines, from baby care and oral hygiene to pain relief and skincare, making it a household name across multiple demographics and geographic regions. While specific customer names are not disclosed, Kenvue’s reach extends to millions of households, pharmacies, and healthcare providers globally.

Investment Thesis

▲ Bull case

Kenvue is positioned to benefit from sustained market share gains in its Self Care segment despite organic sales headwinds, driven by strategic brand activations and innovations that are not fully reflected in near-term financials but are building long-term consumer loyalty and prescription strength. The company gained market share in the U.S. Self Care business despite a reduction in seasonal incidences, with share improvement fueled by innovations and strong brand activations like Zyrtec® becoming the first Official Allergy Relief Sponsor of the PGA TOUR, supported by a fully integrated marketing campaign and executional excellence at retail. Additionally, Tylenol® remains the #1 HCP recommended brand for both adults and children, with Average Weekly Recommendations increasing sequentially for both demographics, indicating enduring trust among healthcare professionals that translates into resilient brand equity and repeat purchasing behavior. These share gains, particularly in Europe, Middle East and Africa (EMEA) and Asia Pacific for Nicorette® and in North America for core brands, suggest that underlying demand strength is being masked by transient factors like weak cold and flu seasons and trade inventory adjustments, setting the stage for accelerated growth when seasonal patterns normalize and supply chain efficiencies from the Vue Forward initiative fully materialize.
The Skin Health and Beauty segment demonstrates robust organic growth fueled by a powerful innovation pipeline and geographic diversification that is reducing reliance on any single market, with significant upside potential as eCommerce acceleration and brand-specific campaigns gain traction globally. Organic sales grew 5.0% in Q1 FY26, driven by 4.2% volume growth and 0.8% favorable value realization, with strong performance across EMEA, Latin America, and Asia Pacific accompanied by sequential improvement in North America. This growth was fueled by a robust pipeline of innovations—including Neutrogena®’s entry into Sun Care in select EMEA markets and the launch of OGX® Pro Growth in North America and EMEA—and sharp brand activations, coupled with targeted actions to accelerate demand in the eCommerce channel and a solid sun season in Latin America amplified by strong commercial execution on Neutrogena® Sun. The segment’s ability to deliver growth across all major need states and regions, combined with improving trends in North America, indicates that the business is overcoming historical regional volatility and building a more resilient, globally balanced growth engine that is less susceptible to seasonal or macroeconomic fluctuations in any one area.
Kenvue’s financial transformation through cost optimization and restructuring is creating operating leverage that will significantly expand margins as the 2026 Restructuring Initiative scales, with current adjusted metrics already reflecting substantial efficiency gains that are underappreciated by the market focused solely on GAAP results. Q1 FY26 adjusted operating income margin expanded to 24.0% from 19.8% in the prior year period, reflecting benefits from cost optimization actions including the Vue Forward and 2026 Restructuring Initiative, which drove a year-over-year reduction in selling, general, and administrative expenses alongside media cost improvements. This margin expansion occurred despite inflation, tariffs, and lower volumes, highlighting the potency of productivity gains from global supply chain optimization and favorable value realization. With the 2026 Restructuring Initiative expected to incur approximately $250 million in pre-tax restructuring expenses in FY26—front-loaded in early quarters—the full annual benefit of these efficiencies will begin to flow through in subsequent quarters, meaning current adjusted profitability understates the run-rate earnings power that will emerge as the initiative matures and cost savings compound.
The pending acquisition by Kimberly-Clark represents a near-term catalyst that is likely to unlock significant strategic and financial value beyond the current standalone trajectory, with integration planning already identifying substantial synergies in go-to-market efficiency, supply chain optimization, and cross-brand innovation that management is not emphasizing in current communications due to transaction sensitivities. Kimberly-Clark’s April 15 announcement of the post-close organizational structure—featuring a fast-and-lean, balanced matrix approach with market-owned business end-to-end and functions bringing best capabilities to markets at speed—is designed to drive durable, repeatable growth by capitalizing on the generational opportunity ahead. This structure, combined with Kimberly-Clark’s Powering Care strategy, positions the combined entity to accelerate innovation, expand access to trusted brands, and deliver increased benefits to consumers globally, suggesting that Kenvue’s current standalone performance undervalues the upside potential of being integrated into a larger, more scalable platform with enhanced R&D, distribution, and marketing capabilities that will accelerate post-close value creation.

Kenvue is positioned to benefit from sustained market share gains in its Self Care segment despite organic sales headwinds, driven by strategic brand activations and innovations that are not fully reflected in near-term financials but are building long-term consumer loyalty and prescription strength. The company gained market share in the U.S. Self Care business despite a reduction in seasonal incidences, with share improvement fueled by innovations and strong brand activations like Zyrtec® becoming the first Official Allergy Relief Sponsor of the PGA TOUR, supported by a fully integrated marketing campaign and executional excellence at retail. Additionally, Tylenol® remains the #1 HCP recommended brand for both adults and children, with Average Weekly Recommendations increasing sequentially for both demographics, indicating enduring trust among healthcare professionals that translates into resilient brand equity and repeat purchasing behavior. These share gains, particularly in Europe, Middle East and Africa (EMEA) and Asia Pacific for Nicorette® and in North America for core brands, suggest that underlying demand strength is being masked by transient factors like weak cold and flu seasons and trade inventory adjustments, setting the stage for accelerated growth when seasonal patterns normalize and supply chain efficiencies from the Vue Forward initiative fully materialize.
The Skin Health and Beauty segment demonstrates robust organic growth fueled by a powerful innovation pipeline and geographic diversification that is reducing reliance on any single market, with significant upside potential as eCommerce acceleration and brand-specific campaigns gain traction globally. Organic sales grew 5.0% in Q1 FY26, driven by 4.2% volume growth and 0.8% favorable value realization, with strong performance across EMEA, Latin America, and Asia Pacific accompanied by sequential improvement in North America. This growth was fueled by a robust pipeline of innovations—including Neutrogena®’s entry into Sun Care in select EMEA markets and the launch of OGX® Pro Growth in North America and EMEA—and sharp brand activations, coupled with targeted actions to accelerate demand in the eCommerce channel and a solid sun season in Latin America amplified by strong commercial execution on Neutrogena® Sun. The segment’s ability to deliver growth across all major need states and regions, combined with improving trends in North America, indicates that the business is overcoming historical regional volatility and building a more resilient, globally balanced growth engine that is less susceptible to seasonal or macroeconomic fluctuations in any one area.
Kenvue’s financial transformation through cost optimization and restructuring is creating operating leverage that will significantly expand margins as the 2026 Restructuring Initiative scales, with current adjusted metrics already reflecting substantial efficiency gains that are underappreciated by the market focused solely on GAAP results. Q1 FY26 adjusted operating income margin expanded to 24.0% from 19.8% in the prior year period, reflecting benefits from cost optimization actions including the Vue Forward and 2026 Restructuring Initiative, which drove a year-over-year reduction in selling, general, and administrative expenses alongside media cost improvements. This margin expansion occurred despite inflation, tariffs, and lower volumes, highlighting the potency of productivity gains from global supply chain optimization and favorable value realization. With the 2026 Restructuring Initiative expected to incur approximately $250 million in pre-tax restructuring expenses in FY26—front-loaded in early quarters—the full annual benefit of these efficiencies will begin to flow through in subsequent quarters, meaning current adjusted profitability understates the run-rate earnings power that will emerge as the initiative matures and cost savings compound.
The pending acquisition by Kimberly-Clark represents a near-term catalyst that is likely to unlock significant strategic and financial value beyond the current standalone trajectory, with integration planning already identifying substantial synergies in go-to-market efficiency, supply chain optimization, and cross-brand innovation that management is not emphasizing in current communications due to transaction sensitivities. Kimberly-Clark’s April 15 announcement of the post-close organizational structure—featuring a fast-and-lean, balanced matrix approach with market-owned business end-to-end and functions bringing best capabilities to markets at speed—is designed to drive durable, repeatable growth by capitalizing on the generational opportunity ahead. This structure, combined with Kimberly-Clark’s Powering Care strategy, positions the combined entity to accelerate innovation, expand access to trusted brands, and deliver increased benefits to consumers globally, suggesting that Kenvue’s current standalone performance undervalues the upside potential of being integrated into a larger, more scalable platform with enhanced R&D, distribution, and marketing capabilities that will accelerate post-close value creation.

▼ Bear case

Kenvue faces persistent and worsening volume declines in its core Self Care segment that signal underlying demand weakness not offset by pricing or innovation, with organic sales trends deteriorating despite favorable mix shifts and external tailwinds that may not be sustainable. The Self Care segment reported a 2.3% organic sales decline in Q1 FY26, driven by a 3.9% volume decrease only partially offset by 1.6% favorable value realization, with weak cold and flu seasons across major markets cited as a primary factor—yet this follows a 3.1% volume decline in Q4 FY25, indicating a consistent pattern of volume erosion that cannot be explained solely by seasonality. Smoking cessation growth behind Nicorette® in EMEA and Asia Pacific was insufficient to offset broader category weakness, and while Tylenol® maintained HCP recommendation status, the company did not disclose whether Average Weekly Recommendations translated into actual prescription volume or retail sales growth, raising concerns that brand trust is not converting to consumption. This suggests that value realization gains may be reaching their limits, and without meaningful volume recovery, the segment’s long-term growth profile remains impaired by structural shifts in consumer behavior toward private label, alternative remedies, or reduced OTC utilization.
The company’s reliance on foreign currency benefits to flatter reported sales growth obscures a fundamental lack of organic momentum, with currency tailwinds contributing disproportionately to headline results and creating a misleading impression of business health that could reverse abruptly with macroeconomic shifts. Q1 FY26 net sales increased 4.5% versus the prior year, but this was driven by a 3.8% foreign currency benefit, with organic sales growth of only 0.7%—meaning over 84% of the reported sales increase came from currency effects rather than underlying business performance. Similarly, in Skin Health and Beauty, 4.2% of the 8.4% net sales increase came from foreign currency, and in Essential Health, 3.4% of the 4.9% increase was currency-driven. This heavy dependence on currency tailwinds implies that the underlying business is growing at a near-stagnant pace, and any reversal in foreign exchange rates—particularly a strengthening U.S. dollar—would immediately erase reported growth and expose the fragility of the organic sales foundation, especially given that the company provided no guidance on currency-neutral outlook beyond the current quarter.
Mounting legal and reputational risks surrounding Tylenol®’s perceived link to autism and ADHD during pregnancy are creating persistent headwinds that are not fully mitigated by corporate messaging, with real-world behavioral impacts already observed in healthcare settings and regulatory environments that could impair long-term brand viability. A March Reuters analysis of U.S. emergency room prescribing patterns found that Tylenol use among pregnant women fell 10% overall after President Trump linked acetaminophen to autism, with orders for women aged 15–44 dipping 16% initially and a 20% weekly decline in the third week—indicating that thousands of women avoided pain or fever treatment due to unfounded fears. Although Kenvue stated the claims were unfounded and acetaminophen remains the safest option, the fact that a Texas judge rejected Kenvue’s bid to dismiss a lawsuit by Attorney General Ken Paxton over failure to warn consumers about Tylenol’s supposed links to autism and ADHD suggests ongoing legal exposure that could result in costly settlements, mandated label changes, or restrictions on marketing. Furthermore, while European and Danish studies have found no causal link, the U.S. FDA is initiating a label change process to warn of potential autism and ADHD risks, and until that is resolved, the brand remains vulnerable to erosion of trust among key demographics, particularly pregnant women and pediatricians, which could have disproportionate impact given Tylenol®’s central role in the Self Care and Essential Health portfolios.
The pending acquisition by Kimberly-Clark introduces significant execution and integration risks that could undermine value creation, with the company providing minimal detail on how operational disruptions, cultural clashes, or overlooked synergies might affect performance during the transition period, despite acknowledging that the transaction remains subject to foreign regulatory approvals and customary closing conditions. While Kimberly-Clark announced its post-close organizational structure in April, Kenvue has not disclosed any specific integration readiness metrics, employee retention plans, or contingency strategies for managing supply chain, IT systems, or commercial operations during the window between announcement and close—expected in the second half of 2026. The 2026 Restructuring Initiative, which aims to optimize the operating model and reduce complexity, may conflict with or duplicate efforts required for Kimberly-Clark integration, potentially leading to wasted spending or operational confusion. Additionally, the company disclosed that pending transaction and other related costs were $16 million in Q1 FY26 (vs. $0 in the prior year), with no breakdown of what these costs entail, raising concerns that transaction-related expenses could escalate unpredictably and distract management from core business execution, particularly as the company shifts focus from standalone performance to deal readiness without clear communication on how day-to-day operations will be safeguarded.

Kenvue faces persistent and worsening volume declines in its core Self Care segment that signal underlying demand weakness not offset by pricing or innovation, with organic sales trends deteriorating despite favorable mix shifts and external tailwinds that may not be sustainable. The Self Care segment reported a 2.3% organic sales decline in Q1 FY26, driven by a 3.9% volume decrease only partially offset by 1.6% favorable value realization, with weak cold and flu seasons across major markets cited as a primary factor—yet this follows a 3.1% volume decline in Q4 FY25, indicating a consistent pattern of volume erosion that cannot be explained solely by seasonality. Smoking cessation growth behind Nicorette® in EMEA and Asia Pacific was insufficient to offset broader category weakness, and while Tylenol® maintained HCP recommendation status, the company did not disclose whether Average Weekly Recommendations translated into actual prescription volume or retail sales growth, raising concerns that brand trust is not converting to consumption. This suggests that value realization gains may be reaching their limits, and without meaningful volume recovery, the segment’s long-term growth profile remains impaired by structural shifts in consumer behavior toward private label, alternative remedies, or reduced OTC utilization.
The company’s reliance on foreign currency benefits to flatter reported sales growth obscures a fundamental lack of organic momentum, with currency tailwinds contributing disproportionately to headline results and creating a misleading impression of business health that could reverse abruptly with macroeconomic shifts. Q1 FY26 net sales increased 4.5% versus the prior year, but this was driven by a 3.8% foreign currency benefit, with organic sales growth of only 0.7%—meaning over 84% of the reported sales increase came from currency effects rather than underlying business performance. Similarly, in Skin Health and Beauty, 4.2% of the 8.4% net sales increase came from foreign currency, and in Essential Health, 3.4% of the 4.9% increase was currency-driven. This heavy dependence on currency tailwinds implies that the underlying business is growing at a near-stagnant pace, and any reversal in foreign exchange rates—particularly a strengthening U.S. dollar—would immediately erase reported growth and expose the fragility of the organic sales foundation, especially given that the company provided no guidance on currency-neutral outlook beyond the current quarter.
Mounting legal and reputational risks surrounding Tylenol®’s perceived link to autism and ADHD during pregnancy are creating persistent headwinds that are not fully mitigated by corporate messaging, with real-world behavioral impacts already observed in healthcare settings and regulatory environments that could impair long-term brand viability. A March Reuters analysis of U.S. emergency room prescribing patterns found that Tylenol use among pregnant women fell 10% overall after President Trump linked acetaminophen to autism, with orders for women aged 15–44 dipping 16% initially and a 20% weekly decline in the third week—indicating that thousands of women avoided pain or fever treatment due to unfounded fears. Although Kenvue stated the claims were unfounded and acetaminophen remains the safest option, the fact that a Texas judge rejected Kenvue’s bid to dismiss a lawsuit by Attorney General Ken Paxton over failure to warn consumers about Tylenol’s supposed links to autism and ADHD suggests ongoing legal exposure that could result in costly settlements, mandated label changes, or restrictions on marketing. Furthermore, while European and Danish studies have found no causal link, the U.S. FDA is initiating a label change process to warn of potential autism and ADHD risks, and until that is resolved, the brand remains vulnerable to erosion of trust among key demographics, particularly pregnant women and pediatricians, which could have disproportionate impact given Tylenol®’s central role in the Self Care and Essential Health portfolios.
The pending acquisition by Kimberly-Clark introduces significant execution and integration risks that could undermine value creation, with the company providing minimal detail on how operational disruptions, cultural clashes, or overlooked synergies might affect performance during the transition period, despite acknowledging that the transaction remains subject to foreign regulatory approvals and customary closing conditions. While Kimberly-Clark announced its post-close organizational structure in April, Kenvue has not disclosed any specific integration readiness metrics, employee retention plans, or contingency strategies for managing supply chain, IT systems, or commercial operations during the window between announcement and close—expected in the second half of 2026. The 2026 Restructuring Initiative, which aims to optimize the operating model and reduce complexity, may conflict with or duplicate efforts required for Kimberly-Clark integration, potentially leading to wasted spending or operational confusion. Additionally, the company disclosed that pending transaction and other related costs were $16 million in Q1 FY26 (vs. $0 in the prior year), with no breakdown of what these costs entail, raising concerns that transaction-related expenses could escalate unpredictably and distract management from core business execution, particularly as the company shifts focus from standalone performance to deal readiness without clear communication on how day-to-day operations will be safeguarded.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Household & Personal Products

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	PG	PROCTER & GAMBLE Co	341.94 Bn	20.49	3.94	37.03 Bn
2	UL	Unilever Plc	131.50 Bn	27.72	3.97	32.92 Bn
3	CL	Colgate Palmolive Co	72.27 Bn	32.63	3.48	7.94 Bn
4	KVUE	Kenvue Inc.	36.23 Bn	22.34	2.37	8.66 Bn
5	KMB	Kimberly Clark Corp	35.62 Bn	89.49	2.15	7.08 Bn
6	EL	Estee Lauder Companies Inc	28.99 Bn	-151.78	1.95	7.31 Bn
7	CHD	Church & Dwight Co Inc /De/	22.75 Bn	24.31	407.73	2.40 Bn
8	CLX	Clorox Co /De/	12.26 Bn	14.78	1.81	2.49 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password